Gyre Therapeutics (GYRE) Registration Filing summary

Company overview and business model

• Commercial-stage biotechnology company focused on anti-inflammatory and anti-fibrotic drugs for organ diseases, with a core emphasis on organ fibrosis.

• Operates primarily through a majority-owned subsidiary in China, Beijing Continent Pharmaceutical Co., Ltd. (Gyre Pharmaceuticals).

• Key products include ETUARY (pirfenidone) for idiopathic pulmonary fibrosis (IPF) and nintedanib, with plans to commercialize nintedanib in China in 2025.

• Pipeline includes F351 (lead candidate for liver fibrosis), F573 (caspase inhibitor for liver failure), F230 (for pulmonary arterial hypertension), and F528 (for COPD).

• Recent approvals include avatrombopag for thrombocytopenia associated with chronic liver disease, with commercialization planned for 2025.

Financial performance and metrics

• Pro forma combined revenues for the year ended December 31, 2023, were $113.5 million.

• Pro forma net loss attributable to common stockholders for 2023 was $96.7 million, with a basic and diluted net loss per share of $1.26.

• Significant operating expenses include R&D ($15.1 million), selling and marketing ($61.2 million), and acquired in-process R&D ($83.1 million).

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for development, manufacturing, scale-up, working capital, and general corporate purposes.

• May allocate a portion to license, acquire, or invest in new programs or drug development activities, though no current commitments exist.

• Pending use, proceeds may be invested in interest-bearing, investment-grade securities or government securities.